BSC Business/EH&S Overview More than 25 Years Advancing the Practice of Less-Invasive Medicine Narrative: This presentation provides an overview of Boston Scientific. The presentation is focused on a corporate level. If you require more detail at the business or product level, other presentation materials are available that offer more details.

Boston Scientific Corporation Profile Boston Scientific is a global, multi-billion dollar company focused on less-invasive medical devices and procedures Boston Scientific Corporation Profile General Facts: Founded in 1979 with 38 employees, $2 million in sales. Now Fortune 500 company World’s largest medical device company dedicated to less-invasive therapies Portfolio of 15,000 products, many with market leading positions The TAXUS® drug eluting stent has been the most successfully launched product in the history of the industry Corporate HQ: Natick, MA Regional HQs: Singapore, Paris, Tokyo Website: www.bostonscientific.com Product Innovation: 9,000+ Patents issued $569 Million invested in R&D (’04) $1.2 Billion in 22 Investments (’04) Financials: $5.6 Billion Revenue (’04) 27.5% CAGR* (’01-’04) $1.4 Billion Net Income (’04) NYSE: BSX Narrative: Here are some fast facts on Boston Scientific. (You can read from the slide on individual bullet points) Be sure to make the following points: We are a global company with a 25 year track record of innovation and success. We have been a pioneer in our industry and continue to be a leading innovator with major internal and external R&D investments. We are coming off our most successful year in company history, driven largely by the success of the TAXUS drug eluting stent – the most successful product launch in medical device history. We operate manufacturing facilities in the U.S., Ireland and Costa Rica and have direct marketing and sales operations in 40 countries. Our international presence helps us accelerate the time within which new products can be brought to market and gain access to worldwide technological developments that may be implemented across product lines. Demographics: 17,500+ Employees Direct marketing & sales in more than 40 countries 16 Primary manufacturing locations in U.S., Ireland & Costa Rica * Compound Annual Growth Rate

Boston Scientific products help treat a broad range of medical conditions throughout the body NEUROMODULATION NEUROVASCULAR PERIPHERAL VASCULAR ELECTROPHYSIOLOGY VASCULAR SURGERY CARDIOVASCULAR ONCOLOGY Narrative: Boston Scientific develops, manufactures and markets technologies that are used to treat a wide range of medical conditions throughout the body through the use of less-invasive procedures. We cater to a broad and diverse set of medical professionals including interventional cardiologists, gastroenterologists, oncologists, gynecologists and pain specialists. The medical specialty names used on this slide correspond to Boston Scientific’s various businesses, which will be explained in more detail in a later slide. ENDOSCOPY GYNECOLOGY UROLOGY

BOSTON SCIENTIFIC FACTS Boston Scientific offers market leading technologies for many of the most prevalent and debilitating diseases DISEASE PREVALENCE BOSTON SCIENTIFIC FACTS Cardiovascular Disease accounts for more than 40 percent of all deaths in U.S. BSC interventional cardiology products are used in about one million procedures annually Neurovascular Disease is one of the leading causes of death in the U.S. BSC’s is a leading supplier of products for neurovascular intervention with less-invasive technologies under investigation for treating intra- cranial atherosclerotic and carotid artery disease Abdominal Aortic Aneurysm (AAA) more than one million Americans have AAA; a significant portion can be treated with early detection BSC is a worldwide leader of surgical aortic repair and currently has less-invasive technology in development Peripheral Vascular Disease afflicts approximately 3.7 million people in the U.S. and is a common condition in Americans 65 and older BSC is a leader in peripheral vascular treatment Heart Arrhythmias as many as two million Americans are living with atrial fibrillation, with about 160,000 new cases each year, increasing patient’s chances of stroke by five times BSC’s cardiac ablation procedures are used in 80 percent of the electrophysiology labs in the U.S. Incontinence affects approximately 13 million adults in the U.S., occurring in women twice as often as men More than 20,000 women per year are treated with BSC’s urinary incontinence products Kidney Stones more than one million Americans are treated for kidney stones each year Worldwide, nearly 350,000 patients annually are treated with BSC’s kidney stone-related devices Uterine Fibroids develop in 25 percent of all women at some point in their lives, and nearly six million cases are left untreated BSC’s Uterine fibroid embolization is a growing alternative treatment, with >13,000 procedures performed in 2004 Pancreaticobiliary Disease (gallstones) more than 500,000 Americans undergo gallbladder surgery each year BSC Endoscopy is a market leader in endoscopic devices to treat gallstones Narrative: Boston Scientific develops products that help treat some of the most devastating diseases and medical conditions that afflict millions of lives each year. Here is just a sample of some of the more serious disease states, along with the effects they have on the population. The last column in the table shows how Boston Scientific is making strides towards providing better outcomes for patients suffering from these conditions. Read slide for details

Peripheral Dilatation Catheters / Guidewires Over 25 years of Innovation has led to a broad portfolio of more than 15,000 products Sampling of Boston Scientific’s Product Portfolio Balloons Detachable Coils Grafts Enteral Feeding Ablation Embolics Cardiac Mapping Stents Stone Retrieval Embolic Protection Narrative Boston Scientific pioneered the use of less-invasive medical devices to treat patients. Many of our products are catheter-based and use the body’s venous system or other natural openings to gain access to the afflicted area. Our expansive product portfolio includes more than 15,000 products that treat a variety of medical conditions throughout the body. The diversity of our product portfolio allows us to provide a comprehensive range of treatment options. Through internal development and strategic acquisition of proprietary and leading technologies, we continue to add to our product capabilities. Peripheral Dilatation Biopsy Systems Ureteral Stents Catheters / Guidewires Neuro-stimulation

Guidant Acquisition Redefining “Bold” Consistent with BSC Strategy Long-term interest in CRM DES Alternative Diversification and Growth

Boston Scientific is organized into three major groups and eleven distinct businesses 2004 Revenues $5.6 Billion Interventional Cardiology Peripheral Interventions Vascular Surgery Neurovascular Electrophysiology Cardiovascular Urology Gynecology Endoscopy Oncology Endosurgery Neuromodulation Auditory Pain Management Groups Businesses Narrative: We will now look at how Boston Scientific is structured to deliver its innovative products. In an effort to best serve our customers, the Company aligned its sales and marketing organizations and centralized them under three groups: Cardiovascular, Endosurgery and Neuromodulation. Each group is further divided into distinct business units, with a total of eleven for the entire company. Cardiovascular is the largest and includes: Interventional Cardiology, Peripheral Interventions, Vascular Surgery, Neurovascular and Electrophysiology. Our Endosurgery group, which recently relocated to our new Marlborough, MA campus, is comprised of Endoscopy, Oncology, Urology and Gynecology The Neuromodulation group is a recent expansion to our Company’s footprint and is a result of the acquisition of Advanced Bionics in 2004. The group includes Auditory and Pain Management businesses. We will now take a more detailed look at each of the three major groups. Cardiovascular ’04 Revenue = $4.480B % Company Total = 80% Endosurgery ’04 Revenue = $1.088B % Company Total = 19% Neuromodulation ’04 Revenue = $46M % Company Total = 1%

Boston Scientific has evolved from early pioneer to industry leader Global Leadership in Interventional Medicine $6,283 TAXUS DES U.S. FDA approval Revenue ($000) Begins first clinical trial of DES BSC acquires eight companies in two years Phase IV Next Chapter BSC goes public with IPO on NYSE Narrative: Boston Scientific has evolved over the past 25 years in three phases, or chapters, as depicted in this graph showing our annual revenues. During Phase I, we paved the way as an industry pioneer, breaking new ground in medical devices for more than three decades – even prior to the official formation of Boston Scientific. Throughout our history, Boston Scientific has developed many groundbreaking technologies and grown many of the businesses that can be credited with the advancement of the industry. However, it was during Phase II of our growth where we made some of our most important strategic acquisitions including Scimed Life Sciences, which became the foundation for our Cardiovascular business. Other key acquisitions included Target Therapeutics, Schneider, Symbiosis Corp. and EP Technologies. During this time the company grew from 2,800 employees to more than 10,000. Facilities grew by more than one million square feet while the product line expanded from 3,000 to 8,500 items. The most recent chapter, Phase III, involved building our operational effectiveness, focusing on obtaining approval of our TAXUS drug-eluting coronary stent system, and the successful execution of the TAXUS launch. This chapter culminated with Boston Scientific as the worldwide leader in coronary stent sales, which drove explosive growth in revenues. Today we continue to grow and build diverse product offerings through product development, strategic acquisitions and alliances with third parties. The strength of our portfolio, our physician relationships and our people allow Boston Scientific to begin the next chapter in our history and continue to be a global leader in the medical device industry. John Abele and Pete Nicholas partner to form Boston Scientific Phase I Less-Invasive Medicine Pioneer/Leader Phase II Strategic Mass (Via Acquisitions) Phase III Stent Integration & DES Leadership

We Achieve Global Leadership in our Key Markets Interventional Cardiology 90%+ of sales from market leading products Represents 73% of BSC total business Endosurgery (Endoscopy, Oncology, Urology, Gynecology) 75% of sales from market leading products Represents 19% of BSC total business Narrative: The strength of our market share in our served markets stems from the quality, breadth and diversity of our product lines, which permit medical specialists to satisfy many of their less-invasive device requirements from a single source. In our largest business segment, Interventional Cardiology, we hold a leading position in the market with 45% market share. Even if you exclude our biggest product line, drug-eluting stents, we still retain 43% market share, indicating that we hold a deep and broad presence in this market. In the Endosurgery market, which makes up nearly one-fifth of the Company’s business, we hold a leading market share position that is more than double that of our closest competitor in a highly competitive and diverse marketplace. At the product line level, the bulk of our sales come from market leading products. At Boston Scientific, our goal is to develop market leading products that adhere to the highest standards of quality, safety and efficacy.

BSC has made significant internal R&D investments to champion new ideas and products into new markets New Product Development Delivering what’s next.TM R&D Investment $Millions U.S. Patents Issued At year-end 2004: 6,000+ applications pending worldwide Narrative: The data presented here provides testament to the first track of our Hybrid Model – our Internal investment. We are investing in new technologies across all areas of the Company, resulting in a strong and growing patent portfolio. These numbers represent our investment in internally developed technologies and include investments designed to enable the rapid and critical expansion of our clinical affairs capabilities. The pace of innovation in the medical device industry demands sound trials to support regulatory requirements and to demonstrate safe and effective clinical performance. Our consistently expanding investment in new technology supports our mission of “Delivering What’s Next” in less-invasive therapies.

The result of our Hybrid Model is a Robust Product Pipeline Product Priorities that will shape our future Cardiac Rhythm Management (CRM) Cameron Health cardioverter defibrillator Endovascular Aortic Repair (EVAR) TriVascular AAA Stent Graft 1 Next-Generation Drug-Eluting Stents TAXUS® Liberté™ 2 Carotid Stent EndoTex NexStent 1 1. CAUTION: Investigational device. Limited by Federal law to investigational use. 2. Not available for sale in the United States. 3. Humanitarian Use Device. Pain Management Precision Spinal Cord Stimulation System bion Microstimulator 1 Single-Use Endoscope Endovations Endoscopy Suite Neurovascular Stent Wingspan™ Stent System with Gateway PTA Balloon Catheter3 Shown here are 8 Product Priorities representing innovative technologies under development that are intended to fuel the next stage of our growth and shape our Company’s future (refer to slide). None of these devices is yet approved for use (with the exception of PRECISION SCS system). Cardiac Rhythm Management (CRM) - The Cameron Health implantable cardioverter defibrillator is designed to sense and stabilize abnormal heart rhythm without being connected to the heart with wire leads. Carotid Stent – The EndoTex NexStent is designed for the treatment of carotid artery disease.* Endovascular Aortic Repair (EVAR) - The TriVascular AAA Stent Graft device is intended to offer a long-awaited, low-profile endovascular approach to repair abdominal aortic aneurysms.* Next-Generation Drug-Eluting Stent - TAXUS Liberté is designed to offer improved deliverability and conformability in challenging anatomy. ** Single-Use Endoscope – Endovations is a fully integrated digital endoscopy system designed to increase procedural efficiencies. It offers physicians a single-use endoscope with improved ergonomics for ease of use. Wingspan Stent System – The Wingspan Stent System is designed to treat atherosclerotic lesions or accumulated plaque in brain arteries. The product is approved as a Humanitarian Use Device only. Pain Management (PRECISION) – The PRECISION Spinal Cord Stimulation System applies electrical impulses to the nerves, which mask pain signals to aid in the management of chronic trunk and limb pain. Pain Management (bion) – The bion Microstimulator, a miniature neurostimulator designed to treat migraine – with a minimally invasive implantation procedure.* Additional opportunities that Boston Scientific is pursuing include: Intracranial stenting, EP Ablation, EP Navigation, Peripheral stenting, Tumor Ablation, Bladder cancer, Uterine fibroids, Incontinence therapy * CAUTION: Investigational device. Limited by Federal law to investigational use. ** Not available for sale in the United States.

What Defines the BSC EH&S Program Focus and clarity Measuring our contribution; we put points on the board Ruthless prioritization; we drive what matters Compliance as a given; integrity in our actions Developing integrated business-driven solutions

Environmental Management Systems Injury Incidence and Severity Rates Highly Valued Aspects Environmental Management Systems Injury Incidence and Severity Rates GHG Emissions/Energy Efficiency Risk Compliance

TRIR

LWR

Global Ergonomics Initiative ( a.k.a. ergo-lean) Premise: Wasted Motion/Posture, Frequency and Force = Ergonomic Risk and Inefficiencies Approach: Provide Fast and Quantitative “Same as Same” Tools Across Sites Integrating into Lean Manufacturing

Results Summary Risk Reductions Ranging Between 25-80% New York Forecasting $670 K Income Increase Using FORM (3X) Based Upon Measured Cycle Time Costa Rica Forecasting $5.1 MM Income Increase using FORM (8X) Based Upon Measured Output Tullamore Projecting 27% Cycle Time Improvement with 8 FTE’s Freed, 20% Reduction in Floor Space We Put Points on the Board

Why ISO-14001 Certification Our Most Effective Response to Environmental Tender Requests; Currently at 70+% VOP Focused “Aspects Analysis” Will Drive the Correct Environmental Elements Supports BSC Environmental Program and External Perception

Expanding Environmental program Desire to Have BSC Recognized as an Environmental Leader Are Examining all BSC Environmental Aspects Premise is Based on “Triple Win” Elements

Choosing our Business Partners BSC is a performance based company, “Delivering what’s next” Partners need to be performance, not process, based We expect the best people We look for team culture, with the ability to listen, and the courage to lead We expect fair pricing We watch accountability

Thank You